Pioglitazone hydrochloride

GPR40 agonist 6 (Compound 7a) is a potent and selective free fatty acid receptor 1 ( FFAR1 or GPR40 ) agonist with an EC 50 of 0.058 μMIn VitroGPR40 agonist 6 (Compound 7a) shows a very favorable ADME profile, and shows no significant inhibition of

GSK-269984A is a Prostaglandin E2 Receptor 1 (EP1) antagonist with a pIC 50 of 7.9.In VitroResults from [ 3 H]-PGE 2 binding assay in CHO cells overexpressing the human EP 1 receptor demonstrate that GSK-269984A is an antagonist of EP 1 receptor

GSK-269984A is a Prostaglandin E2 Receptor 1 (EP1) antagonist with a pIC 50 of 7.9.In VitroResults from [ 3 H]-PGE 2 binding assay in CHO cells overexpressing the human EP 1 receptor demonstrate that GSK-269984A is an antagonist of EP 1 receptor

InformationGSK-F1 is a novel potent inhibitor of phosphatidylinositol 4-kinase alpha (PI4KA).

Information:GSK-F1 is a novel potent inhibitor of phosphatidylinositol 4-kinase alpha (PI4KA).

Information:GSK-F1 is a novel potent inhibitor of phosphatidylinositol 4-kinase alpha (PI4KA).

Information:GSK-F1 is a novel potent inhibitor of phosphatidylinositol 4-kinase alpha (PI4KA).

An inactive control for the selective PAD4 inhibitors, GSK484 and GSK199 (IC₅₀s &gt100 &microM).

An inactive control for the selective PAD4 inhibitors, GSK484 and GSK199 (IC₅₀s &gt100 &microM).

A selective androgen receptor modulator.

InformationGSK5182 GSK5182, 4-hydroxytamoxifen analog, is a specific inverse agonist of estrogen-related receptor γ (ERRγ) that inhibits pro-inflammatory cytokine-induced catabolic factors.TargetsERRγ.

An SGK1 inhibitor (IC₅₀s = 62 and 103 nM for SGK1 and SGK2, respectively) that demonstrates greater than 30-fold selectivity for SGK1 over Akt and other related kinases inhibits the androgen-stimulated growth of human prostate carcinoma